Treatment of patients with end-stage kidney disease (ESKD) in the United States accounted for expenditures of approximately $50 billion in 2020.1 This spending was largely attributed to costs associated with dialysis care and inpatient hospitalizations.1 One means of reducing potentially avoidable inpatient hospitalizations is to ensure safe and effective use of medications. Patients with ESKD being treated with dialysis are especially vulnerable to toxicity from medications excreted by the kidneys and those that are nondialyzable.